We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01753375
Recruitment Status : Unknown
Verified December 2012 by AlJohara M AlQuaiz, M.D., King Saud University.
Recruitment status was:  Not yet recruiting
First Posted : December 20, 2012
Last Update Posted : December 20, 2012
Information provided by (Responsible Party):
AlJohara M AlQuaiz, M.D., King Saud University

Brief Summary:
Vitamin D3 supplementation reduces the incidence of multiple sclerosis.Although clinical cross-sectional studies have demonstrated vitamin D3 as a positive mediator in preventing relapses and disease progression, prospective randomized control trials are nevertheless necessary to confirm these statements and to determine the most efficacious, safe, and the minimum required doses. This hypothesis is going to be tested through a randomized triple blinded controlled trial in which after randomization, one group of patients will receive vitamin D and second group will receive placebo. Both groups are going to be followed in a similar way over a period of one year with follow ups at 4, 8 and 12 months. Vitamin D levels is going to be performed at 0,4, 12 month interval. MRI is going to be done at the beginning and end of trial.The number of relapses and the physical disability will be calculated through the Expanded disability status scale (EDSS).

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Dietary Supplement: Vitamin D3 Dietary Supplement: Placebo Phase 2

Detailed Description:

Study Objectives:

  • To estimate the prevalence of vitamin D deficiency in Saudi Multiple Sclerosis(MS) patient coming to King Khalid hospital, multiple sclerosis clinic.
  • To compare the difference in the relapse rate among Multiple Sclerosis patients who are taking vitamin D3 (50,000 IU per week) versus those who are not taking Vitamin D3 supplements.
  • To assess and compare the improvement in the Expanded Disability Status scale and clinical symptoms among those who are taking vitamin D3 versus those who are on placebo

Study Design: A single centre, triple-blinded, parallel randomized placebo controlled trial.

Methods: All eligible patients with clinical definite MS will be assigned a computer-generated Identification number by the statistician and through randomization divided into two groups, one group receiving vitamin D3 (the intervention arm) and other getting placebo (the control arm). All patients will continue with their routine pre-intervention trial treatment for relapse and remission phases of multiple sclerosis. The first treatment group will receive 50,000 IU units of vitamin D3 per week . The control arm patients, instead of vitamin D3 will receive a placebo supplement that looks, smells and tastes the same as the vitamin D3 for 52 weeks. Compliance with the study treatment will be verified by asking the patients about missed doses and by counting used and unused bottles.

All patients will be asked questions related socio-demographic data, vitamin D related dietary products, physical activity questions, exposure to sunlight and variation according to season, use of sunscreen, body coverage when in sunlight and any previous treatment for Multiple Sclerosis, including any vitamin D supplements. Every follow up visit shall include documentation of complete neurologic and medical history and findings. This will be a triple-blinded trial. The patient, the treating physician and the statistician will be masked to the type of treatment each patient receives.Sealed envelopes containing the vitamin D3 or placebo are going to be handed over to the physician with the computer assigned number of the patient. At each follow-up visit all patients will be required to bring their envelopes along with empty/ filled bottles to assess their compliance with the treatment.

The treating physician will follow all the patients at set regular intervals: 0 (baseline), 4, 8, and 12 months to assess the relapses and the EDSS scores and also to check for any adverse effects arising because of the vitamin D3 supplements. Patients who are going to miss their appointment shall be contacted by the project staff to set another appointment in the subsequent week. All patients are going to be emphasized about the importance of these clinical visits and their compliance with the treatment. All patients will be evaluated by the same treating physician.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Role of Vitamin D on the Relapse Rate of Multiple Sclerosis
Study Start Date : January 2013
Estimated Primary Completion Date : July 2014
Estimated Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Vitamin D3
Administered orally on weekly basis
Dietary Supplement: Vitamin D3
Vitamin D3 given as 50000 IU orally on weekly basis

Placebo Comparator: Placebo
To be administered orally on weekly basis
Dietary Supplement: Placebo
Placebo to be given orally on weekly basis

Primary Outcome Measures :
  1. Relapse rate in patients with Multiple Sclerosis [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Improvement in the expanded disability status scores after receiving vitamin D3 [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age between 18-55 years
  • Confirmed Multiple Sclerosis diagnosis according to McDonald criteria
  • Stable neurological functioning for at least one month prior to study entry
  • Expanded Disability Scale score (EDSS) less than <_4.0
  • Must have had one clinical attack in past two years and at least one new silent T2 or gadolinium-enhancing lesion on MRI within the past one year.
  • Willing to participate for the entire 52-week period

Exclusion Criteria:

  • pregnant or nursing.
  • Connective tissue disease (SLE, Sjogren's disease)
  • Endocrine disease (hyperthyroidism, hyperparathyroidism)
  • Any medical condition predisposing to hypercalcaemia, nephrolithiasis or renal insufficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01753375

Layout table for location contacts
Contact: Prof. Abdulkader Daif, M.D 0966-0504205164 adaif@ksu.edu.sa

Layout table for location information
Saudi Arabia
Multiple Sclerosis clinic, Department of Neurology, King Khalid Hospital
Riyadh 11321, Saudi Arabia, 231831
Sponsors and Collaborators
AlJohara M AlQuaiz, M.D.
Layout table for investigator information
Principal Investigator: AlJohara M AlQuaiz, M.D King Saud University- Medical college

Layout table for additonal information
Responsible Party: AlJohara M AlQuaiz, M.D., Executive Director of "Princess Nora Chair for Women Health Research" , Associate Professor and Consultant Family Physician, Department of Family and Community Medicine, King Saud University
ClinicalTrials.gov Identifier: NCT01753375    
Other Study ID Numbers: E12816
First Posted: December 20, 2012    Key Record Dates
Last Update Posted: December 20, 2012
Last Verified: December 2012
Keywords provided by AlJohara M AlQuaiz, M.D., King Saud University:
Multiple Sclerosis
Relapsing rate
Expanded disability status scale
Vitamin D3
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Vitamin D
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents